Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DMAC vs TRVI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DMAC Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 2–3 Matrix Metrics)

DMAC Overall Winner 6-Pillar Tally: DMAC 2 – 2 TRVI (2 Tie) Matrix Metrics: DMAC 2 – 3 TRVI

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) is the stronger overall head-to-head candidate over Trevi Therapeutics, Inc. (TRVI) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). DMAC carries a Unified Composite Score of 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin), whereas TRVI carries 42.6/100 (HOLD) at $13.34 (N/M Forward P/E, 0.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DMAC vs TRVI
DMAC NASDAQ Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 98% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.0 · SMA20: $9.24 · SMA50: $8.24
TRVI NASDAQ
Trevi Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$13.34
-2.27% 1D
Market Cap $1.9B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.49β · 76% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 64.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 45.7 · SMA20: $13.61 · SMA50: $13.95

6-Pillar Scorecard Institutional Category Breakdown (DMAC 2 – 2 TRVI)

Columns: Metric · DMAC · TRVI
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale TRVI
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $503.1M $1.9B
3. Profitability & Quality TRVI
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -114.6% -24.7%
4. Balance Sheet & Cash Flow DMAC
Cash Generation (TTM) -$32M -$62M
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.9M Net Cash $27M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DMAC
Options Structure Phase SURGE CONSOLIDATION
Current IV / %ile 106.3% (14th %ile) 62.3% (8th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DMAC (2) vs TRVI (3)
Institutional Metric DMAC TRVI Criterion Row Edge
Market Capitalization
Scale
$503.1M $1.9B Larger Scale TRVI
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-114.6% -24.7% Higher ROE TRVI
52-Week Range Position
Momentum
55% ($5–$11) 34% ($10–$20) Stronger Trend DMAC
Beta / 30D Volatility
Risk Regime
1.74β · 98% Vol 1.49β · 76% Vol Lower Realized Risk TRVI
Unified Institutional Score
Composite Signal
46.3 / 100 (HOLD) 42.6 / 100 (HOLD) Higher Composite DMAC
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$32M ($4.9M Net Cash) -$62M ($27M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TRVI +1.13 pp
DMAC: +11.16% · TRVI: +12.29%
3M Horizon DMAC +56.5 pp
DMAC: +27.31% · TRVI: -29.19%
6M Horizon DMAC +48.82 pp
DMAC: +48.15% · TRVI: -0.67%
1Y Horizon DMAC +38.86 pp
DMAC: +55.26% · TRVI: +16.4%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DMAC vs TRVI. Trailing 12-month operating profitability (DMAC 0.0% vs TRVI 0.0%) and valuation multiples (DMAC N/M vs TRVI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DMAC ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-114.6% · N/M
TRVI ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-24.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TRVI CONSOLIDATION
103d in phase · OBV DISTRIBUTION
Current IV 62.3%
IV Percentile 8th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact TRVI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TRVI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DMAC vs TRVI Key Questions & Quantitative Answers

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) is the stronger overall head-to-head candidate over Trevi Therapeutics, Inc. (TRVI) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). DMAC carries a Unified Composite Score of 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin), whereas TRVI carries 42.6/100 (HOLD) at $13.34 (N/M Forward P/E, 0.0% operating margin). Technically, DMAC sits in a Neutral phase (RSI 46.0, SURGE options structure) and TRVI sits in a Neutral phase (RSI 45.7, CONSOLIDATION options structure).

TRVI leads the Growth & Scale pillar: DMAC posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with TRVI at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, DMAC generates N/A in USD-normalized revenue versus N/A for TRVI. In operating R&D and SG&A reinvestment, DMAC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TRVI.

DMAC and TRVI trade at balanced relative valuation multiples. DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas TRVI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DMAC (-114.6% ROE) versus TRVI (-24.7% ROE) capital efficiency.

In options market volatility and institutional positioning, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk). By comparison, TRVI carries 62.3% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.49β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.